FLX 787

Drug Profile

FLX 787

Alternative Names: FLX787; TRP activators - Flex Pharma; TRPA1 activators - Flex Pharma; TRPV1 activators - Flex Pharma

Latest Information Update: 16 May 2017

Price : $50

At a glance

  • Originator Flex Pharma
  • Class Small molecules
  • Mechanism of Action TRPA1 protein stimulants; TRPV cation channel agonists; TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis; Multiple sclerosis
  • Phase I Motor neuron disease
  • Preclinical Neuromuscular disorders

Most Recent Events

  • 02 Jun 2017 Flex Pharma plans a phase II trial for Amyotrophic lateral sclerosis in USA, in 2017
  • 02 Jun 2017 Flex Pharma plans to initiate the randomised, controlled, double blinded, parallel-design, phase II COMMIT trial in patients with Charcot-Marie-Tooth in USA, in 2017.
  • 26 Apr 2017 Flex Pharma announces intention to submit an IND application to USFDA for Charcot-Marie-Tooth
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top